How Does Aprotinin Work? Mechanism of Action, Per the Research

What Aprotinin Is and Where It Is Given

Aprotinin is a prescription medicine administered by specialists in a clinical setting, typically a hospital operating room, an infusion area or a critical care unit, where a treating team controls administration, timing and monitoring. It is not a product a person handles independently. Structurally it is a small single chain polypeptide of the Kunitz type, and a pharmacologic overview described it as a broad spectrum inhibitor of serine proteases, with plasmin and kallikrein among the enzymes discussed in that pharmacology (PMID 15239552).

At label level, the approved setting for aprotinin has been cardiac surgery, where it was used with the aim of reducing perioperative blood loss, and a review of the current place of aprotinin in bleeding management traced how that indication was withdrawn after safety concerns and later reinstated in some jurisdictions under a narrower restriction (PMID 25440394). Every other application described on this page, including inhalational respiratory work and kidney physiology work, is investigational and has not been established as an approved indication.

This page is for educational purposes only and is not medical advice; consult a licensed physician or the treating specialist team about any question concerning aprotinin, including whether it is relevant to a particular surgical or medical situation.

The Molecular Target: Serine Protease Active Sites

The central mechanism described in the published pharmacology is direct enzyme inhibition rather than receptor signalling. Aprotinin presents a rigid inhibitory loop that inserts into the catalytic cleft of susceptible serine proteases, forming a tight and reversible enzyme inhibitor complex that prevents substrate cleavage. A pharmacologic overview summarised this broad spectrum serine protease inhibition as the unifying explanation for the molecule's varied downstream effects (PMID 15239552). Because the target is a catalytic site shared across an enzyme family, a single molecule touches several physiological systems at once, which is why reviews of antifibrinolytic practice discuss both haemostatic and inflammatory consequences in the same analysis (PMID 32275035).

Enzyme Families Discussed in the Literature

Established Mechanism: Inhibition of Plasmin and Fibrinolysis

The best characterised pharmacological action is antifibrinolytic. Plasmin is the serine protease that degrades fibrin, and blocking its catalytic site slows the breakdown of clot that forms during surgery. A review of antifibrinolytics in cardiac surgery placed aprotinin alongside lysine analogue agents and described how these drugs have been studied for blood conservation in cardiac operations (PMID 32275035). A separate perioperative blood conservation review discussed pharmacological strategies for limiting transfusion requirement in surgery and positioned antifibrinolytic agents within that wider set of approaches (PMID 19448549).

An important distinction appears in that literature. Aprotinin's inhibition of plasmin is a direct enzymatic block at the active site, whereas lysine analogues interfere with plasminogen binding to fibrin. A review of the current place of aprotinin in bleeding management discussed this difference in class when comparing available options for surgical bleeding (PMID 25440394). This distinction is mechanistic description, not a statement that one agent outperforms another in any individual case.

Established Mechanism: Kallikrein, the Contact System and Inflammation

Contact of blood with the artificial surfaces of a cardiopulmonary bypass circuit activates plasma proteases, including kallikrein, and triggers a broad inflammatory cascade. A 2024 review of strategies to attenuate the maladaptive inflammatory response associated with cardiopulmonary bypass examined pharmacological and circuit based approaches to that cascade and discussed protease inhibition among them (PMID 39022594). The pharmacologic overview of aprotinin similarly framed kallikrein inhibition as a component of the drug's profile rather than an incidental effect (PMID 15239552).

Downstream of kallikrein sit the contact activation pathway of coagulation and the generation of vasoactive kinins. Reviews of cardiac surgical pharmacology therefore describe aprotinin as a molecule with both haemostatic and anti inflammatory dimensions, and researchers writing on antifibrinolytics have noted that these overlapping actions complicate attempts to attribute any single clinical observation to one pathway (PMID 32275035).

Proposed and Investigational Mechanisms

Host Protease Inhibition in Respiratory Virus Research

Several enveloped respiratory viruses require cleavage of a surface glycoprotein by host serine proteases before they can enter cells efficiently. A 2023 review described aprotinin in the context of respiratory diseases and summarised the rationale that inhibiting host proteases interferes with this proteolytic activation step (PMID 37446350). A 2024 review focused specifically on inhalational administration of aprotinin for COVID-19 and other viral conditions and reviewed the published work behind that delivery concept (PMID 39000315).

This remains investigational. The mechanism is plausible on protease biology grounds and is supported in reviews of laboratory and early clinical work, but it is not an approved indication, and any decision about an inhalational formulation would rest entirely with a prescribing clinician operating within the approvals of a given jurisdiction (PMID 39000315).

Tubular Proteases, Sodium Channels and Proteinuria

A distinct and mostly preclinical line of research concerns the kidney. In nephrotic syndrome, filtered proteases appear in urine and can cleave the epithelial sodium channel, shifting it toward an activated state. A 2018 study reported that aprotinin prevented proteolytic epithelial sodium channel activation and volume retention in an experimental nephrotic syndrome model (PMID 29042083). A review of proteasuria discussed the broader impact of active urinary proteases on sodium retention in nephrotic syndrome and placed that finding in context (PMID 30597733).

A 2025 review examined the therapeutic potential of tubular serine protease inhibitors in proteinuria and surveyed where this strategy stands as a research direction (PMID 40982254). Work in this area is animal and mechanistic rather than approved practice, and the papers themselves frame it as a hypothesis being tested.

In Vitro Protease Biology That Frames the Target Class

Understanding what aprotinin can and cannot inhibit depends on how individual proteases are characterised in the laboratory. A 2026 in vitro characterisation reported that human CELA1 has pancreatic elastase-like activity, refining how that enzyme is classified within the serine protease family (PMID 41520764). A 2023 comparative study characterised digestive proteases in the gut of a basal deuterostome, illustrating the substrate and inhibitor profiling methods used to assign enzymes to protease classes (PMID 37470128). Neither of these is clinical work, and both are included only to show how protease specificity, the foundation of any inhibitor mechanism, is established experimentally.

Established Versus Proposed at a Glance

Aprotinin Safety Signals: What Studies Report

Mechanism cannot be separated from safety history in this case. A review of the current place of aprotinin in the management of bleeding described how the drug was withdrawn from wide use following safety concerns and later reinstated in certain regions with a restricted indication and conditions attached (PMID 25440394). A review of antifibrinolytics in cardiac surgery discussed that same trajectory when comparing past, present and anticipated future practice with these agents (PMID 32275035).

Because aprotinin is a polypeptide of animal origin, hypersensitivity is a recognised consideration in its pharmacology, and the pharmacologic overview addressed safety alongside the drug's protease inhibitory profile (PMID 15239552). Perioperative blood conservation reviews have likewise framed the choice of any pharmacological blood sparing strategy as a balance of bleeding risk against agent specific risk in a monitored surgical environment (PMID 19448549). None of this substitutes for the full prescribing information or for the judgement of the specialist team responsible for a given case.

Questions a Prescribing Clinician Can Answer

• Whether aprotinin falls within the approved indication for a planned procedure in the relevant jurisdiction, as discussed in reviews of its restricted reinstatement (PMID 25440394).
• How the treating team compares antifibrinolytic options for a specific operation, a comparison addressed in cardiac anaesthesia reviews (PMID 32275035).
• What monitoring the hospital protocol requires during and after administration, since all use occurs under specialist supervision (PMID 19448549).
• How prior exposure or allergy history is assessed before any decision is made (PMID 15239552).

Key Takeaways

1. The molecular mechanism is reversible active site inhibition of serine proteases rather than receptor binding, as summarised in the pharmacologic overview (PMID 15239552).
2. Plasmin inhibition explains the antifibrinolytic profile reviewed in cardiac surgery literature (PMID 32275035).
3. Kallikrein and contact system effects are described alongside the inflammatory response to cardiopulmonary bypass (PMID 39022594).
4. Respiratory antiviral and kidney sodium handling applications are investigational, supported by reviews and animal work rather than approval (PMID 39000315, PMID 29042083).
5. Administration is a specialist activity in a hospital or critical care setting, and every question about use belongs with a prescribing clinician.

References

• Aprotinin: a pharmacologic overview (Orthopedics, 2004)
• The current place of aprotinin in the management of bleeding (Anaesthesia, 2015)
• Antifibrinolytics and cardiac surgery: The past, the present, and the future (Annals of Cardiac Anaesthesia, 2020)
• Strategies to attenuate maladaptive inflammatory response associated with cardiopulmonary bypass (Frontiers in Surgery, 2024)
• Perioperative blood conservation (European Journal of Anaesthesiology, 2009)
• Aprotinin-Drug against Respiratory Diseases (International Journal of Molecular Sciences, 2023)
• Aprotinin (II): Inhalational Administration for the Treatment of COVID-19 and Other Viral Conditions (International Journal of Molecular Sciences, 2024)
• Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome (Kidney International, 2018)
• Proteasuria: The impact of active urinary proteases on sodium retention in nephrotic syndrome (Acta Physiologica, 2019)
• Therapeutic potential of tubular serine protease inhibitors in proteinuria (American Journal of Physiology. Renal Physiology, 2025)
• Human CELA1 has pancreatic elastase-like activity (Biochimie, 2026)
• Characterization of digestive proteases in the gut of a basal deuterostome (The Journal of Experimental Biology, 2023)